NASDAQ: PROK
Prokidney Corp Earnings Dates, Reports, Calls

Prokidney earnings were -$68.4M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest PROK earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$16.7M, down 21.4% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, PROK reported annual earnings of -$61.2M, with 72.5% growth.

PROK earnings history

Current Revenue
$306.0k
Current Earnings
-$68.4M
Current Profit Margin
-22,362.1%

PROK Return on Equity

Current Company
N/A
Current Industry
-60.2%
Current Market
31.5%

PROK undefined

Current Company
-15%
Current Industry
-2.5%
PROK is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when PROK announces earnings.

PROK undefined

Current Company
-18.36%
Current Industry
5.8%
PROK has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

PROK vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
PROK-$62.60M-$68.43MN/A-$0.60
THRD-$52.65M-$53.45MN/A-$1.23
LXRX-$164.27M-$177.30MN/A-$0.51
DBVT-$113.67M-$113.65MN/A-$5.70
FHTX-$71.61M-$80.44MN/A-$1.36

Prokidney Earnings Reports & History FAQ

What were Prokidney's earnings last quarter?

Prokidney (NASDAQ: PROK) reported Q1 2025 earnings per share (EPS) of -$0.13, up 18.75% year over year. Total PROK earnings for the quarter were -$16.73 million. In the same quarter last year, Prokidney's earnings per share (EPS) was -$0.16.

If you're new to stock investing, here's how to buy Prokidney stock.

Is Prokidney profitable or losing money?

As of the last Prokidney earnings report, Prokidney is currently losing money. Prokidney's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$68.43 million, a 93.87% increase year over year.

What was PROK's earnings growth in the past year?

As of Prokidney's earnings date in Q2 2025, Prokidney's earnings has grown year over year. PROK earnings in the past year totalled -$68.43 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.